Rivaroxaban Reduces VTE Risk in Acutely Ill PatientsRivaroxaban Reduces VTE Risk in Acutely Ill Patients

Rivaroxaban was noninferior to enoxaparin for the prevention of asymptomatic proximal or symptomatic venous thromboembolism at day 10 and was superior to enoxaparin for the prevention of the same clinical events at day 35. Treatment with the new oral anticoagulant was associated with a significantly increased risk of bleeding at day 10 and day 35, however. Heartwire
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Cardiology News Source Type: news